High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

>2 years Confirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Oral InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Hydroxycarbamide Medac

Hydroxycarbamide Medac is a medicine used to treat certain blood disorders, including reducing painful crises in sickle cell disease and lowering blood cell counts.

Jakavi

Jakavi is a medicine used to treat certain serious blood disorders that affect bone marrow and blood cell production.

Pegasys

Pegasys is a medicine used to treat hepatitis B and C by helping the body fight the viral infection.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Hydroxycarbamide

Hydroxycarbamide is a substance used to treat certain blood cancers and reduce painful crises in sickle cell disease.

Peginterferon Alfa-2a

Peginterferon Alfa-2a is a substance that stimulates the immune system to help treat chronic hepatitis C and other viral infections.

Ruxolitinib

Ruxolitinib is a substance that blocks cell signals to reduce abnormal blood cell growth and inflammation in certain bone marrow disorders.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Hidroxicarbamida Generis

Hidroxicarbamida Hikma

Hidroxicarbamida Medac

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Centre Hospitalier Universitaire D'Angers

Haematology

Angers, France

Centre Hospitalier Annecy Genevois

Haematology

Annecy, France

Centre Hospitalier Victor Dupouy Argenteuil

Haematology

Argenteuil, France

Sponsor: The University Of Birmingham

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.